Evidence map›Paper›PMID 31170959›Full record

ArticleBMC cancer2019

Programmed expression of pro-apoptotic BMCC1 during apoptosis, triggered by DNA damage in neuroblastoma cells.

Mohammad Sazzadul Islam, Ryo Takano, Tomoki Yokochi, Jesmin Akter, Yohko Nakamura, Akira Nakagawara, Yasutoshi Tatsumi

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. PRUNE2 inhibits progression of colorectal cancerExperimental and therapeutic medicine · 2022
    Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Mohammad Sazzadul IslamDivision of Innovative Cancer Therapeutics, Chiba Cancer Center Research Institute, Chiba, Japan.
Ryo TakanoDivision of Innovative Cancer Therapeutics, Chiba Cancer Center Research Institute, Chiba, Japan.
Tomoki YokochiDivision of Innovative Cancer Therapeutics, Chiba Cancer Center Research Institute, Chiba, Japan.
Jesmin AkterDivision of Innovative Cancer Therapeutics, Chiba Cancer Center Research Institute, Chiba, Japan.
Yohko NakamuraDivision of Innovative Cancer Therapeutics, Chiba Cancer Center Research Institute, Chiba, Japan.
Akira NakagawaraSAGA HIMAT Foundation, Saga, Japan.
Yasutoshi TatsumiDivision of Innovative Cancer Therapeutics, Chiba Cancer Center Research Institute, Chiba, Japan. ytatsumi@chiba-cc.jp.ORCID http://orcid.org/0000-0003-2646-7410
Chiba Cancer Center · JPChiba University · JPFukuoka Tokushukai Hospital · JPSAGA Heavy Ion Medical Accelerator in Tosu · JP

Funding

Japan Agency for Medical Research and Development P-DirectJapan Society for the Promotion of Science 17K10132Japan Society for the Promotion of Science 22791507Japan Society for the Promotion of Science 24249061Japan Society for the Promotion of Science 26461602National Cancer Centre Research and Development Fund (4)
6 · The paper itself

Abstract

backgroundThe multi-functional BMCC1 (BCH motif-containing molecule at the carboxyl terminal region 1)/PRUNE2 plays a clear role in suppression of tumor activity. In the patients with neuroblastoma (NB), reduced expression of BMCC1 in primary tumor tissues was associated with poor prognosis. By contrast, enforced expression of BMCC1 as well as elevated expression of BMCC1 in response to DNA-damage promotes apoptosis by abrogating Akt-mediated survival pathways.

methodsWe addressed molecular mechanisms underlying changes in regulation of BMCC1 expression during the process of apoptosis, which was promoted by a DNA-damaging drug Cisplatin (CDDP), in NB-derived cells.

resultsElevated expression of BMCC1 was identified as an early response to DNA damage, which is accompanied by phosphorylation of ataxia telangiectasia mutated kinase (ATM) and accumulation of E2F1. Indeed, inhibition of ATM using an ATM inhibitor resulted in a decrease in expression of BMCC1 at mRNA levels. In addition, an E2F-binding sight was required for activation of BMCC1 promoter in response to DNA damage. On the other hand, knockdown of E2F1 yielded abrogated induction of BMCC1 in the cells after treatment with CDDP, suggesting that BMCC1 accumulation was caused by ATM-E2F1-dependent transcription. Finally, we demonstrated that full-length BMCC1 was proteolytically cleaved by apoptosis-activated caspase-9 during advanced stages of apoptosis in SK-N-AS cells.

conclusionsIn this study, we demonstrated the programmed expression of full-length BMCC1 in human NB cells undergoing DNA damage-induced apoptosis. The elucidation of the molecular mechanisms controlling the regulation of BMCC1 during apoptosis initiated by DNA damage provides useful information for understanding drug resistance of tumor cells and spontaneous regression of NB.

Indexed as

ApoptosisAtaxia Telangiectasia Mutated ProteinsBinding SitesCaspase 9Cell Line, TumorCell SurvivalCisplatinDNA DamageE2F1 Transcription FactorGene Knockdown TechniquesHumansNeoplasm ProteinsNeuroblastomaPhosphorylationPromoter Regions, GeneticAtaxia Telangiectasia Mutated ProteinsATM protein, humanCaspase 9CisplatinE2F1 protein, humanE2F1 Transcription FactorNeoplasm ProteinsPRUNE2 protein, humanApoptosisBMCC1Caspase-9DNA damageE2F1Neuroblastoma

Identifiers

PMID31170959
PMCPMC6555734
OpenAlexW2948858767

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.